The 'bio-assay' quality of life might be a better marker of disease activity in acromegalic patients than serum total IGF-I concentrations

European Journal of Endocrinology

Volumn 152, Issue 2, 2005, Pages 217-224

  Bonapart, Ingrid E ^a   van Domburg, Ron ^a   ten Have, Saskia M T H ^a   de Herder, Wouter W ^a   Erdman, Ruud A M ^a   Janssen, Joop A M J L ^a   van der Lely, Aart Jan ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LONG ACTING DRUG; OCTREOTIDE; SOMATOMEDIN C;

ABDOMINAL DISCOMFORT; ACROMEGALY; ADULT; AGED; ARTICLE; CANCER PATIENT; CHEMICAL PARAMETERS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE MARKER; DIZZINESS; ERYTHEMA; FEMALE; HEADACHE; HUMAN; INJECTION SITE REACTION; LONG TERM CARE; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; SHORT FORM 36;

ACROMEGALY; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BIOLOGICAL MARKERS; FEMALE; HAPPINESS; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 14644419644     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.01838     Document Type: Article

References (34)

1. Sonino N, Scarpa E, Paoletta A, Fallo F & Boscaro M. Slow-release lanreotide treatment in acromegaly: effects on QoL. Psychotherapy and Psychosomatics 1999 68 165-167.
2. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF & Davis RJ. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. New England Journal of Medicine 2000 342 1171-1177.
3. Webb SM, Prieto L, Badia X, Albareda M, Catala M, Gaztambide S, Lucas T, Paramo C, Pico A, Lucas A, Halperin I, Obiols G & Astorga R. Acromegaly QoL Questionnaire (ACROQOL) a new health-related QoL questionnaire for patients with acromegaly: development and psychometric properties. Clinical Endocrinology Oxford 2002 57 251-258.
4. Johnson MD, Woodburn CJ & Vance ML. QoL in patients with a pituitary adenoma. Pituitary 2003 6 81-87.
5. van der Lely AJ, de Herder WW, Janssen JA & Lamberts SW. Acromegaly: the significance of serum total and free IGF-I and IGF-binding protein-3 in diagnosis. Journal of Endocrinology 1997 155 (Suppl 1 discussion S15-16) S9-13.
6. Melmed S, Jackson I, Kleinberg D & Klibanski A. Current treatment guidelines for acromegaly. Journal of Clinical Endocrinology and Metabolism 1998 83 2646-2652.
7. Melmed S. Tight control of growth hormone: an attainable outcome for acromegaly treatment. Journal of Clinical Endocrinology and Metabolism 1998 83 3409-3410.
8. Sheppard MC. Follow-up of treated acromegaly: similarities and differences in assessing the response to different primary treatment modalities. Growth Hormone and IGF-I Research 2000 10 (Suppl B) S115-S118.
9. Sheppard MC. Primary medical therapy for acromegaly. Clinical Endocrinology 2003 58 387-399.
10. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I & Lombardi G. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. Journal of Clinical Endocrinology and Metabolism 2001 86 2779-2786.
11. Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA & Wardlaw JM. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. Journal of Clinical Endocrinology and Metabolism 2002 87 4554-4563.
12. Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, Barausse M, Albizzi M, Dallabonzana D & Pedroncelli AM. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? Journal of Clinical Endocrinology and Metabolism 2003 88 3090-3098.
13. Lancranjan I, Bruns C, Grass P, Jaquet P, Jervell J, Kendall-Taylor P, Lamberts SW, Marbach P, Orskov H, Pagani G, Sheppard M & Simionescu L. Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients. Metabolism 1996 45 67-71.
14. Stewart PM, Kane KF, Stewart SE, Lancranjan I & Sheppard MC. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. Journal of Clinical Endocrinology and Metabolism 1995 80 3267-3272.
15. Tarlov AR, Ware JE Jr, Greenfield S, Nelson EC, Perrin E & Zubkoff M. The Medical Outcomes Study. An application of methods for monitoring the results of medical care. The Journal of the American Medical Association 1989 262 925-930.
16. McHorney CA, Ware JE Jr, Lu JF & Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Medical Care 1994 32 40-66.
17. McHorney CA, Ware JE Jr & Raczek AE. The MOS 36-item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Medical Care 1993 31 247-263.
18. Ware JE Jr & Sherbourne CD. The MOS36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care 1992 30 473-483.
19. Ware JE Jr, Gandek B, Kosinski M, Aaronson NK, Apolone G, Brazier J, Bullinger M, Kaasa S, Leplege A, Prieto L, Sullivan M & Thunedborg K. The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: results from the IQOLA Project. International QoL Assessment. Journal of Clinical Epidemiology 1998 51 1167-1170.
20. Ware JE Jr & Gandek B. Overview of the SF-36 Health Survey and the International QoL Assessment (IQOLA) Project. Journal of Clinical Epidemiology 1998 51 903-912.
21. Ware JE Jr & Gandek B. Methods for testing data quality, scaling assumptions, and reliability: the IQOLA Project approach. International QoL Assessment. Journal of Clinical Epidemiology 1998 51 945-952.
22. Ware JE Jr & John E Ware Jr on health status and QoL assessment and the next generation of outcomes measurement. Interview by Marcia Stevic and Katie Berry. Journal for Healthcare Quality 1999 21 12-17.
23. Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R, Sprangers MA, te Velde A & Verrips E. Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. Journal of Clinical Epidemiology 1998 51 1055-1068.
24. Juul A, Holm K, Kastrup KW, Pedersen SA, Michaelsen KF, Scheike T, Rasmussen S, Muller J & Skakkebaek NE. Free insulin-like growth factor I serum levels in 1430 healthy children and adults, and its diagnostic value in patients suspected of growth hormone deficiency. Journal of Clinical Endocrinology and Metabolism 1997 82 2497-2502.
25. Ware JE Jr, Kosinski M, Bayliss MS, McHorney CA, Rogers WH & Raczek A. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Medical Care 1995 33 AS264-AS279.
26. Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB & Wilson CB. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. Journal of Clinical Endocrinology and Metabolism 1998 83 3411-3418.
27. Ahmed S, Elsheikh M, Stratton IM, Page RC, Adams CB & Wass JA. Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clinical Endocrinology 1999 50 561-567.
28. Arita K, Kurisu K, Tominaga A, Eguchi K, Iida K, Uozumi T & Kasagi F. Mortality in 154 surgically treated patients with acromegaly - a 10-year follow-up survey. Endocrine Journal 2003 50 163-172.
29. Bates AS, Van't Hoff W, Jones JM & Clayton RN. An audit of outcome of treatment in acromegaly. Quarterly Journal Of Medicine 1993 86 293-299.
30. Beauregard C, Truong U, Hardy J & Serri O. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clinical Endocrinology 2003 58 86-91.
31. Bengtsson BA, Eden S, Ernest I, Oden A & Sjogren B. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Medica Scandinavica 1988 223 327-335.
32. Biermasz NR, Dulken HV & Roelfsema F. Postoperative radiotherapy in acromegaly is effective in reducing GH concentration to safe levels. Clinical Endocrinology 2000 53 321-327.
33. Orme SM, McNally RJ, Cartwright RA & Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. Journal of Clinical Endocrinology and Metabolism 1998 83 2730-2734.
34. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ & Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clinical Endocrinology 1994 41 95-102.